Night work, circadian rhythm disorders and glucose regulation, the GLU24/7 study

Glucometabolic health and cardiovascular risk factors in night shift workers - a protocol for a 2-year longitudinal study in an industrial setting

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10297427

Enrollment

Registered

2025-03-21

Start date

2024-10-03

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Development of cardio-metabolic symptoms in night shift workers Circulatory System

Interventions

During a 6-week baseline period, sleep and physical activity will be monitored using actimetry (Gen 3 health tracker ring, OURA). Continuous glucose monitoring (Freestyle Libre Pro iQ-system, Abbott)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rotating night shift work or day shift work only

Exclusion criteria

Exclusion criteria: Issues with blood pressure

Design outcomes

Primary

Measure	Time frame
1. The following primary outcome variables are assessed during a 6-week baseline period: 1.1. Sleep and physical activity are measured using actimetry with the Gen 3 health tracker ring (OURA) 1.2. Glucose variability is measured using continuous glucose monitoring (CGM) with the Freestyle Libre Pro iQ-system (Abbott) and recorded in a food diary for two weeks. 2. 2. Circadian rhythm is measured by analyzing monocyte mRNA expression using Gene Expression Profiling (Nanostring) at two timepoints in the shift schedule; in the morning after consecutive night shifts or before a day shift in the baseline period.	—

Measure

Time frame

1. The following primary outcome variables are assessed during a 6-week baseline period: 1.1. Sleep and physical activity are measured using actimetry with the Gen 3 health tracker ring (OURA) 1.2. Glucose variability is measured using continuous glucose monitoring (CGM) with the Freestyle Libre Pro iQ-system (Abbott) and recorded in a food diary for two weeks. 2. 2. Circadian rhythm is measured by analyzing monocyte mRNA expression using Gene Expression Profiling (Nanostring) at two timepoints in the shift schedule; in the morning after consecutive night shifts or before a day shift in the baseline period.

—

Secondary

Measure	Time frame
The following secondary outcome cardiovascular disease (CVD) risk factors are assessed during a 6-week baseline period and at a 2-year follow-up: 1. Cardiometabolic blood parameters measured using Luminex or ELISA 2. Markers of inflammation measured using Luminex or ELISA 3. Lipid profile measured using enzymatic assays on a Cobas 8000 4. Blood pressure and resting heart rate (RHR) measured after a 5-minute seated rest from the subject’s left arm utilizing a BpTRU device 5. Arterial stiffness measured carotid to femoral pulse wave velocity (cfPWV) using SphygmoCor XCEL instrument 6. Carotid intima-media thickness (cIMT) measured using ultrasound scanning of both common carotid arteries proximal to the carotid bifurcation 7. Cardiorespiratory fitness measured using a cycle ergometer to measure maximal oxygen uptake (V?O2max)	—

Measure

Time frame

The following secondary outcome cardiovascular disease (CVD) risk factors are assessed during a 6-week baseline period and at a 2-year follow-up: 1. Cardiometabolic blood parameters measured using Luminex or ELISA 2. Markers of inflammation measured using Luminex or ELISA 3. Lipid profile measured using enzymatic assays on a Cobas 8000 4. Blood pressure and resting heart rate (RHR) measured after a 5-minute seated rest from the subject’s left arm utilizing a BpTRU device 5. Arterial stiffness measured carotid to femoral pulse wave velocity (cfPWV) using SphygmoCor XCEL instrument 6. Carotid intima-media thickness (cIMT) measured using ultrasound scanning of both common carotid arteries proximal to the carotid bifurcation 7. Cardiorespiratory fitness measured using a cycle ergometer to measure maximal oxygen uptake (V?O2max)

—

Countries

Norway

Contacts

Public ContactFred Haugen

fred.haugen@stami.no+4723195100

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026